La cadena de opciones muestra datos clave de las opciones de acciones de Prothena Corp a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Prothena Corp..

Prothena Corp (NASDAQ:PRTA) Bolsa, Cadena de Opciones

Prothena Corp

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Prothena Corporation plc - Ordinary Shares

Prothena Corp PLC

Shares of IMAC Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) rose sharply in today's pre-market trading after the company announced it launched Ignite Proteomics, <a href="https://www.benzinga.com/quote/BACK">its new subsidiary</a>.
IMAC shares jumped 108.6% to $1.73 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Dunxin Financial Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXF#NYSE">DXF</a>) gained 110.6% to $16.32 in pre-market trading after dipping 73% on Monday.</li>
<li>Planet Image International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YIBO#NASDAQ">YIBO</a>) rose 85.7% to $5.72 in pre-market trading following a 43% surge on Monday.</li>
<li>ZK International Group Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZKIN#NASDAQ">ZKIN</a>) gained 47% to $0.9998 in pre-market trading after the company reported a year-over-year increase in FY24 EPS results.</li>
<li>Hepion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) gained 32.7% to $0.2191 in pre-market trading after falling 13% on Monday. Hepion Pharmaceuticals recently announced a $9 million public offering.</li>
<li>Pulmonx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) gained 27.2% to $8.00 in pre-market trading.</li>
<li>JIADE Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) rose 26.1% to $1.11 in pre-market trading after gaining around 18% on Monday.</li>
<li>Unity Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNTY#NASDAQ">UNTY</a>) gained 23.7% to $59.99 in pre-market trading.</li>
<li>Concentra Group Holdings Parent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) shares jumped 14.6% to $26.99 in pre-market trading. Concentra recently announced a 5.5% increase in preliminary fourth-quarter 2024 revenue.</li>
<li>Empire Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EP#NYSE">EP</a>) rose 8.2% to $6.50 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Evergreen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGR#NASDAQ">EVGR</a>) shares fell 58.3% to $5.00 in pre-market trading.</li>
<li>Greenlight Capital Re, Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLRE#NASDAQ">GLRE</a>) shares fell 49.1% to $7.00 in pre-market trading.</li>
<li>Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) dipped 41.1% to $6.00 in pre-market trading.</li>
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) declined 31.4% to $11.01 in pre-market trading.</li>
<li>The Joint Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) fell 27.3% to $8.10 in today's pre-market trading. The Joint Corp recently announced a year-over-year increase in patient visits.</li>
<li>Varex Imaging Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) shares dipped 26% to $10.10 in pre-market trading. Varex Imaging will report unaudited financial results for the first quarter of fiscal year 2025 on Thursday, Feb. 6.</li>
<li>Champions Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) fell 22.2% to $9.10 in pre-market trading.</li>
<li>EVI Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVI#NYSE">EVI</a>) shares tumbled 13.1% to $16.20 in pre-market trading. EVI Industries recently announced plans to acquire Haiges Machinery.</li>
<li>Scholar Rock Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) fell 13% to $37.00 in pre-market trading.</li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) fell 9.6% to $11.81 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43230206/jim-cramer-is-worried-about-this-consumer-cyclical-stock-7-yield-something-may-be-wrong-here">Jim Cramer Is Worried About This Consumer Cyclical Stock: 7% Yield? &#8216;Something May Be Wrong Here&#8217;</a></li>
</ul>

Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo analyst Tiago Fauth initiated coverage on MannKind Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) with an Overweight rating and announced a price target of $9. MannKind shares closed at $6.30 on Thursday. See how other analysts view this stock.</li>
<li>Citigroup analyst Peter Christiansen initiated coverage on S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Buy rating and announced a price target of $600. S&amp;P Global shares closed at $486.56 on Thursday. <a href="https://www.benzinga.com/quote/SPGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexander Hess initiated coverage on Fair Isaac Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Neutral rating and announced a price target of $2150. Fair Isaac shares closed at $2,044.89 on Thursday. <a href="https://www.benzinga.com/quote/FICO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Andrew Fein initiated coverage on Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy rating and announced a price target of $72. Avidity Biosciences shares closed at $31.05 on Thursday. See how other analysts view this stock.</li>
<li>Chardan Capital analyst Rudy Li initiated coverage on Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy rating and announced a price target of $40. Prothena shares closed at $16.01 on Thursday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SPGI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095106/image-183-1024x589.png" alt="" class="wp-image-701945" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095106/image-183-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095106/image-183-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095106/image-183-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095106/image-183.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

News

Initiation

Markets

Trading Ideas

FICO

MNKD

SPGI

This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Throughout the last three months, 6 analysts have evaluated Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Prothena Corp, presenting an average target of $51.5, a high estimate of $84.00, and a low estimate of $22.00. This current average represents a 17.2% decrease from the previous average price target of $62.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1734699613_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Prothena Corp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Prothena Corp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Prothena Corp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Prothena Corp's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Prothena Corp</h2>
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
<h3>Financial Insights: Prothena Corp</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Challenges: Prothena Corp's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -98.86%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -6082.58%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Prothena Corp's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -10.57%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Prothena Corp's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -9.51%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Prothena Corp's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Prothena Corp: Insights From 6 Analyst Reviews

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and lowers the price target from $84 to $48.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Prothena Corp, Lowers Price Target to $48

Chardan Capital analyst Rudy Li initiates coverage on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy rating and announces Price Target of $40.

Chardan Capital Initiates Coverage On Prothena Corp with Buy Rating, Announces Price Target of $40

B of A Securities analyst Tazeen Ahmad maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Neutral and lowers the price target from $26 to $22.

B of A Securities Maintains Neutral on Prothena Corp, Lowers Price Target to $22

On Thursday, Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) released results from the Phase 2b PADOVA study of prasinezumab in early-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42568873/roches-phase-iib-study-of-prasinezumab-missed-primary-endpoint-but-suggests-possible-clinical-bene" rel="noreferrer noopener">stage Parkinson&#8217;s disease</a>.
Partner Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) conducted the 586-subject study investigating prasinezumab in early-stage Parkinson&#8217;s disease patients who had been treated for a minimum of 18 months while on stable symptomatic treatment.
Prasinezumab <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2024-12-19" rel="noreferrer noopener">showed</a> a potential clinical effect in the primary endpoint of time to confirmed motor progression with an HR=0.84 and p=0.0657, missing statistical significance.
The companies said the effect of prasinezumab was more pronounced in a pre-specified analysis in the population treated with levodopa (75% of participants), HR=0.79 and nominal p=0.0431.
Pre-specified supplementary covariate-adjusted analyses of these endpoints demonstrated nominally significant effects on the primary endpoint (HR=0.81; nominal p=0.0334) and in the levodopa subgroup (HR=0.76; nominal p=0.0175).
Consistent positive trends across multiple secondary and exploratory endpoints were also observed. Prasinezumab continues to be well tolerated, and no new safety signals were observed in the study.
The Phase 2 PASADENA and Phase 2b PADOVA open-label extension studies will continue to explore the observed effects in both studies.
Roche will continue to evaluate the data and work together with health authorities to determine the next steps.
Full results from the PADOVA study will be presented at an upcoming medical meeting.
Price Action: PRTA stock is up 32.40% at $15.83 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42561240/salesforces-ai-powered-agentforce-20-spurs-analyst-upgrades-and-growth-optimism" target="_blank" rel="noreferrer noopener">Wall Street Analysts Are Bullish On Salesforce&#8217;s AI Vision &#8211; Here&#8217;s Why</a></li>
</ul>

Biotech

Large Cap

Health Care

Movers

General

RHHBY

Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits

U.S. stocks were higher, with the Dow Jones index gaining over 150 points on Thursday.
Shares of Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) rose sharply in today's session after the company reported better-than-expected first-quarter financial results and raised FY25 <a href="https://www.benzinga.com/24/12/42586612/accenture-delivers-q1-revenue-growth-bolstered-by-consulting-and-managed-services">revenue growth outlook</a>.
On Thursday, Accenture reported first-quarter fiscal 2025 sales of $17.69 billion compared with the analyst consensus estimate of $17.12 billion, up 9% year-over-year in U.S. dollars and 5% in local currency.
Accenture shares jumped 7% to $372.09 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares jumped 68% to $12.55 after the company's Narsoplimab met pivotal trial primary endpoint.</li>
<li>Soho House &amp; Co Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NASDAQ">SHCO</a>) gained 54% to $7.57 after the company received a $9.00 per share acquisition offer from a consortium backed by Executive Chairman Ron Burkle and Yucaipa. The board has formed a special committee to evaluate the proposal.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 35% to $16.55. On Wednesday, the FDA approved Mesoblast's Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S.</li>
<li>Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) gained 21.7% to $1.3990.</li>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) surged 20.3% to $23.63.</li>
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) gained 17.8% to $14.09 after the Phase IIb Prasinezumab study showed potential in early Parkinson&#8217;s disease.</li>
<li>Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) rose 14.3% to $182.79 after the company reported better-than-expected second-quarter EPS and issued better-than-expected FY25 revenue outlook.</li>
<li>Innodata Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) gained 14.2% to $39.09. Wedbush analyst Daniel Ives initiated coverage on Innodata with an Outperform rating and announced a price target of $48.</li>
<li>Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) gained 10.1% to $4.16. Valneva expanded Chikungunya vaccine access in Asia through partnership with Serum Institute.</li>
<li>Tripadvisor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) rose 8.8% to $14.10. Tripadvisor and Liberty TripAdvisor announced a planned merger.</li>
<li>Nordstrom, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) shares gained 4.8% to $23.98.</li>
<li>CarMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) shares rose 4.5% to $85.08 after the company reported better-than-expected quarterly earnings and sales.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42591599/att-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-thursday">AT&amp;T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday</a></li>
</ul>

Intraday Update

INOD

MESO

MVST

OMER

SHCO

TRIP

VALN

Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday

WIIM

Prothena shares are trading higher after the Phase IIb Prasinezumab study showed potential in early Parkinson's disease.

3 analysts have expressed a variety of opinions on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Prothena Corp and provided 12-month price targets. The average target is $66.33, accompanied by a high estimate of $84.00 and a low estimate of $31.00. A 1.0% drop is evident in the current average compared to the previous average price target of $67.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731513622_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Prothena Corp among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Prothena Corp. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Prothena Corp's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Prothena Corp's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Prothena Corp</h2>
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
<h3>Financial Milestones: Prothena Corp's Journey</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Prothena Corp's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3184.75% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Prothena Corp's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 50.67% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Prothena Corp's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 12.34%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Prothena Corp's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.54% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.02, Prothena Corp adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Prothena Corp

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and maintains $84 price target.

HC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $84 Price Target

The estimated full year 2024 net cash used from operating and investing activities is primarily driven by an estimated net loss of $120 to $135 million, which includes an estimated $48 million of non-cash share-based compensation expense.
 &nbsp;

Guidance

Prothena Continues To Expect 2024 Net Cash Used In Operating And Investing Actives To Be $148M - $160M And Expects To End Year With $468M (Midpoint) In Cash, Cash Equivalents And Restricted Cash

Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(1.18) by 6.78 percent. This is a 389.47 percent decrease over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $970.00 thousand which missed the analyst consensus estimate of $1.23 million by 20.85 percent. This is a 98.86 percent decrease over sales of $84.87 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Prothena Corp Q3 2024 GAAP EPS $(1.10) Beats $(1.18) Estimate, Sales $970.00K Miss $1.23M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Prothena Corp to report an earnings per share (EPS) of $-1.17.
Prothena Corp bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
The company's EPS beat by $2.27 in the last quarter, leading to a 4.42% increase in the share price on the following day.
Here's a look at Prothena Corp's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.05</td>
<td>-1.20</td>
<td>-1.22</td>
<td>-0.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.22</td>
<td>-1.34</td>
<td>-1.26</td>
<td>0.38</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-4.0%</td>
<td>-2.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731333694_0.png" alt="eps graph" />
<h3>Prothena Corp Share Price Analysis</h3>
Shares of Prothena Corp were trading at $17.7 as of November 07. Over the last 52-week period, shares are down 49.89%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/PRTA/earnings">To track all earnings releases for Prothena Corp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Prothena Corp

U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Monday.
Shares of PROCEPT BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results and raised its <a href="https://www.benzinga.com/quote/PRCT/earnings">FY24 revenue guidance</a>.
PROCEPT BioRobotics shares jumped 25% to $85.87 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Monte Rosa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares jumped 60.5% to $7.85 after the company announced a global license agreement with Novartis to advance VAV1 MGDs. The company will receive a $150 million upfront payment and is eligible for additional milestone payments.</li>
<li>EyePoint Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) gained 33.6% to $12.69 after the company showed early trial data for DURAVYU for diabetic macular edema and announced improving vision and anatomy.</li>
<li>Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares gained 25.5% to $5.89 after the company announced it entered into the sixth amendment to its exclusive distribution agreement with Teoxane.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) gained 19.5% to $6.36.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) rose 15.3% to $44.91. The stock may be moving amid possible volatility as traders evaluate his chance of winning the 2024 presidential election.</li>
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) surged 15.3% to $17.66.</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) gained 13.8% to $11.09. Ladenburg Thalmann analyst Glenn Mattson initiated coverage on Serve Robotics with a Buy rating and announced a price target of $16.</li>
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) rose 12.1% to $46.05 after the company reported 96-week eGFR stabilization on Saturday for its Phase 2b study of IgAN patients with Atacicept.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) gained 10.3% to $19.21.</li>
<li>TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) rose 10.2% to $7.03.</li>
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) gained 9% to $18.03.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) rose 8.3% to $9.45. Canaccord Genuity analyst Brian McNamara maintained Newell Brands with a Buy and raised the price target from $12 to $13.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) gained 7% to $251.00 amid a rise in Bitcoin.</li>
<li>MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) rose 6.3% to $18.14 amid a rise in Bitcoin.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41570746/top-3-real-estate-stocks-that-may-surge-in-q4">Top 3 Real Estate Stocks That May Surge In Q4</a></li>
</ul>

EYPT

GLUE

IBRX

MARA

MNSO

MSTR

PRCT

RVNC

SERV

VERA

WULF

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $50.25, a high estimate of $84.00, and a low estimate of $24.00. A 4.74% drop is evident in the current average compared to the previous average price target of $52.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1727787662_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Prothena Corp by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Prothena Corp. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Prothena Corp's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Prothena Corp's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Prothena Corp: A Closer Look</h2>
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
<h3>A Deep Dive into Prothena Corp's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Prothena Corp showcased positive performance, achieving a revenue growth rate of 3184.75% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Prothena Corp's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 50.67% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Prothena Corp's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.34% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Prothena Corp's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.54% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Prothena Corp's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Prothena Corp: 4 Analysts Share Their Views

B of A Securities analyst Tazeen Ahmad maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Neutral and lowers the price target from $33 to $31.

B of A Securities Maintains Neutral on Prothena Corp, Lowers Price Target to $31

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 300 points during on Monday.
The Dow traded down 0.71% to 42,012.42 while the NASDAQ fell 0.52% to 18,026.03. The S&amp;P 500 also fell, dropping, 0.45% to 5,712.53.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/09/41091653/how-to-earn-500-a-month-from-mccormick-stock-ahead-of-q3-earnings">How To Earn $500 A Month From McCormick Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Communication services shares fell by just 0.1% on Monday.
In trading on Monday, materials shares dipped by 1.3%.
Top Headline
Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) posted better-than-expected quarterly earnings.
Carnival posted adjusted earnings of $1.27 per share, beating analysts' estimates of $1.16 per share. The company posted quarterly sales of $7.90 billion versus expectations of $7.83 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>ZEEKR Intelligent Technology Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) shares shot up 9% to $22.95. Shares of US-listed Chinese companies traded higher on continued strength amid stimulus efforts. September PMI data beat estimates but factory activity fell, which may raise stimulus hopes.</li>
<li>Shares of Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) got a boost, surging 13% to $3.9140 after the company announced a strategic research collaboration and license agreement with Bristol Myers Squibb to develop reagents for the next generation of ex vivo T-cell therapies. Also, it announced that it is focusing its pipeline on a set of high value programs.</li>
<li>EMCORE Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMKR#NASDAQ">EMKR</a>) shares were also up, gaining 74% to $2.10 after Mobix Labs submitted an all-cash offer to acquire the company for $3.80 per share.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares dropped 15% to $17.01. Prothena announced leadership team updates. Cantor Fitzgerald analyst Charles Duncan reiterated Prothena with an Overweight rating.</li>
<li>Shares of Heritage Insurance Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTG#NASDAQ">HRTG</a>) were down 20% to $12.44.</li>
<li>Stellantis N.V. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) was down, falling 13% to $13.91 after the company lowered its FY24 guidance.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $68.12 while gold traded down 0.4% at $2,656.90.
Silver traded down 1.5% to $31.33 on Monday, while copper fell 1.1% to $4.5490.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.98%, Germany's DAX fell 0.76% and France's CAC 40 dipped 2.00%. Spain's IBEX 35 Index fell 0.76%, while London's FTSE 100 fell 1.01%.
The British economy grew by 0.5% on quarter during the second quarter, down from 0.7% in the first quarter, while the UK's current account deficit widened to £28.4 billion in the second quarter, versus a revised £13.8 billion in the prior quarter. Net consumer credit in the U.K. rose by £1.3 billion in August, from £1.2 billion in the previous month. German import prices increased by 0.2% year-over-year in August compared to a 0.9% rise in July.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 dipping 4.80%, Hong Kong's Hang Seng Index jumping 2.43%, China's Shanghai Composite Index gaining 8.06% and India's BSE Sensex falling 1.49%.
Japan&#8217;s housing starts fell by 5.1% year-over-year in August compared to a 0.2% decline in the prior month, while industrial production fell by 3.3% month-over-month in August. Retail sales in Japan climbed by 2.8% year-over-year in August.
The official NBS Non-Manufacturing PMI in China fell to 50.0 in September from 50.3 in the prior month, while official NBS Manufacturing PMI climbed to 49.8 in September from 49.1 in August.
Economics
The Chicago PMI rose to 46.6 in September from 46.1 in August versus market estimates of 46.2.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41064318/top-3-real-estate-stocks-that-are-preparing-to-pump-this-month">Top 3 Real Estate Stocks That Are Preparing To Pump This Month</a></li>
</ul>

Equities

Eurozone

Commodities

EMKR

HRTG

PRME

STLA

Dow Dips 300 Points; Emcore Shares Spike Higher

Oppenheimer analyst Jay Olson maintained a Buy rating on Prothena (PRTA – Research Report) today and set a price target of $62.00. The company's sh...

Prothena (PRTA) Receives a Buy from Oppenheimer

Oppenheimer previewed the upcoming year for the firm's Biotechnology coverage and said the firm's top ideas for 2025 are Capricor (CAPR), Gilead (G...

Capricor, Gilead, Kymera, Praxis among Oppenheimer's top biotech picks for 2025

Roche, Prothena miss main goal in mid-stage trial for Parkinson's drug

Oppenheimer lowered the firm's price target on Prothena (PRTA) to $58 from $62 and keeps an Outperform rating on the shares. The company announced ...

Prothena price target lowered to $58 from $62 at Oppenheimer

RBC Capital keeps a Sector Perform rating on Prothena (PRTA) after the company's partner Roche (RHHBY) presented topline data from the Phase IIb PA...

RBC sees justification for Prothena rebound after study miss

BofA analyst Tazeen Ahmad lowered the firm's price target on Prothena (PRTA) to $22 from $26 and keeps a Neutral rating on the shares after the com...

Prothena price target lowered to $22 from $26 at BofA

Chardan initiated coverage of Prothena (PRTA) with a Buy rating and $40 price target Prothena "remains a controversial name," and the stock has bee...

Prothena initiated with a Buy at Chardan

H.C. Wainwright lowered the firm's price target on Prothena (PRTA) to $48 from $84 and keeps a Buy rating on the shares after the Phase 2b PADOVA s...

Prothena price target lowered to $48 from $84 at H.C. Wainwright

Comments

Prothena Corp

Prothena Corp (PRTA) Opciones

Prothena Corp (NASDAQ:PRTA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL